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Over the last two decades, various studies have shown consistent
improvement in the overall prognosis of children with B-cell non-
Hodgkin’s lymphoma (B-NHL) (Philip et al, 1982; Al-Attar et al,
1986; Patte et al, 1990). This is attributable to both a reduction in
early toxic deaths (Lynch et al, 1977; Allegretta et al, 1985; Miron
et al, 1997) and a decrease in relapse rate following an increase in
the intensity of systemic and central nervous system (CNS)-
directed therapy (Hann et al, 1990; Patte et al, 1991; Cairo et al,
1996). This improvement in the results of treatment has involved
patients with all stages of disease (Pinkerton et al, 1991; Patte et al,
1997; Atra et al, 1998). Radiotherapy no longer appears to have a
role in the treatment of primary CNS disease (Patte et al, 1986;
Bowman et al, 1996), and radical surgery with its potential risks,
has become unnecessary (Al-Attar et al, 1989; Miron et al, 1997).
Relapse still occurs and is the principle cause of treatment failure.
Patients who relapse after first-line chemotherapy can occasion-
ally be salvaged with more intensive chemotherapy with or
without megatherapy and stem cell rescue (Philip et al, 1993;
Sweetenham et al, 1994).
The United Kingdom Children Cancer Study Group (UKCCSG)
9002 protocol was based on the French LMB-84 and it involved
3 months of treatment with sequential doses of chemotherapy
including intrathecal (i.t.) therapy. No radiotherapy was given. We
report the results of this regimen in the treatment of children with
stage III and IV B-NHL (L3-blasts up to 70% in the bone marrow).
The prognostic significance of serum lactate dehydrogenase
(LDH) level at diagnosis, tumour substage and time to achieve
complete remission (CR) were prospectively analysed in an
attempt to identify different risk groups and to facilitate delivery of
risk-directed therapy in the future.
PATIENTS AND METHODS
Children under 18 years with newly diagnosed Murphy stage III or
IV B-NHL and up to 70% FAB L3-type blasts in the bone marrow
(but with no CNS disease), with B-cell histology (Burkitt’s or
Burkitt’s-like or large cell) and/or phenotype (surface membrane
immunoglobulin-positive) were eligible for this protocol. This is
the group of patients identified by the LMB group to be of
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Summary From July 1990 to March 1996, 112 children with stage III or IV B-cell non-Hodgkin’s lymphoma (B-NHL) with up to 70% FAB L3-
type blasts (n = 42) in the bone marrow without central nervous system (CNS) disease were treated on the United Kingdom Children Cancer
Study Group (UKCCSG) 9002 protocol (identical to the French LMB 84). The median age was 8.3 years. There were 81 boys and 31 girls.
According to the extent of the primary disease, patients were sub-staged into three groups: IIIA with unresectable abdominal tumour (n = 39);
IIIB with abdominal multiorgan involvement (n = 57) and IIIX with extra-abdominal primary lymphoma often presenting as pleural effusion
(n = 16). Univariate and multivariate analyses were carried out to evaluate the prognostic significance of lactate dehydrogenase (LDH) level
at diagnosis, the sub-stage and the time to achieve complete remission (CR). With a median follow up of 48 months (range 12–92), the overall
and event free survival (EFS) is 87% (95% confidence interval (CI) 79.2–92.1%) and 83.7% (95% CI 76.3–89.2%) respectively. Six patients
(5.4%) never achieved CR, of whom one is alive following high-dose therapy. Eight patients (7.1%) relapsed after achieving CR, three are
alive after second-line therapy. There were three early toxic deaths (2.7%), mainly from infection, and one late death from a second cancer.
There was no significant difference in EFS according to LDH level at diagnosis, the sub-stage or the time to CR. This study confirms the
overall good prognosis and low rate of toxic deaths in patients with advanced B-NHL treated with this intensive regimen. No significant
difference in EFS according to the sub-stage, the time to achieve CR or LDH level at diagnosis making it difficult to identify a group that should
not receive intensive therapy. © 2000 Cancer Research Campaign
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‘standard risk’. Those with up to 70% L3-type blasts in the bone
marrow but no blasts in peripheral blood (who would be defined
by the Murphy scheme as B-ALL) are included. Informed consent
was obtained from all patients and their parents as appropriate.
Staging investigations included bilateral bone marrow aspirates,
cerebrospinal fluid (CSF) cell count and cytospins, a chest
radiograph and ultrasonography, with or without computerized
tomography (CT) scan of the primary tumour. All pathology
specimens, biopsies, pleural or ascitic fluid, bone marrows and
CSF were reviewed centrally. Surgical attempts were limited to
obtain adequate biopsy material for histopathological diagnosis.
One hundred and thirteen consecutively diagnosed and previ-
ously untreated patients were entered between July 1990 and
March 1996 (one patient was identified after entering the study to
be HIV-positive and was subsequently excluded from the
analysis). Eighty-one patients were boys and 31 girls. Ages at
diagnosis ranged from 2.2 to 17.5 years (median 8.3 years). For
the purpose of this study, patients were substaged according to the
French Society of Paediatric Oncology (SFOP) classification, into
two groups according to the extent of primary disease (Philip et al,
1987). Thirty-nine patients were stage IIIA as defined by the pres-
ence of limited but unresectable disease usually localized to the
abdomen with or without ascites. Patients with abdominal primary
and multi-organ involvement, e.g. kidney, liver or ovary (n = 57),
were classified as IIIB. As patients with extra-abdominal primary
B-NHL, particularly those with pleural involvement often
presenting with effusion, are believed to have a worse outcome
(Sandlund et al, 1990); in this study those are classified as IIIX
(n = 16). Among the 112 patients, 42 had involvement of the bone
marrow at diagnosis with up to 70% L3-blasts. No patient included
in this study had CNS disease at diagnosis.
The schema and details of the UKCCSG 9002 protocol are
shown in Figure 1 and Table 1 respectively. The first course of
treatment consisted of low-dose cyclophosphamide, vincristine
and prednisolone (COP) in an attempt to avoid severe drug toxi-
city, often associated with tumour lysis syndrome at diagnosis.
This course could be repeated 1 week later if the clinical condition
of the patient remained poor before proceeding with the more
intensive treatment of cyclophosphamide, vincristine, pred-
nisolone, doxorubicin and high-dose methotrexate (COPADM).
All patients received regular intrathecal (i.t.) hydrocortisone with
either methotrexate or cytarabine. Patients were assessed clinically
and radiologically to confirm response and exclude progressive
disease after COP. Full assessment was done to confirm CR prior
to the second block of cytarabine and high-dose methotrexate
(CYM2) (Figure 1). Those who achieved CR continued on
protocol. In the absence of CR, patients were treated with more
intensive chemotherapy as in the UKCCSG 9003 protocol (Atra
Table 1 UKCCSG 9002 protocol
Regimen Dose Administration
COP
Cyclophosphamide 300 mg m-2 i.v. bolus day 1
Vincristine 1 mg m-2 i.v. bolus day 1
Prednisolone 60 mg m2 day Oral days 1–7
i.t. MTX + HC day 1
COPADM 1
Vincristine 2 mg m-2 i.v. bolus day 1
Doxorubicin 60 mg m-2 i.v. over 6 h day 2
Cyclophosphamide 250 mg m-2 dose i.v. bolus 12 h days 2–4
(with mesna)
High-dose MTX 3 m-2 i.v. over 3 h day 1
Folinic acid rescue 15 mg m-2 i.v. from day 2
Prednisolone 60 mg m-2 oral days 1–5
i.t. MTX+HC day 2, 6
COPADM 2 as COPADM1 except
Vincristine 2 mg m-2 i.v. bolus day 1, 6
Cyclophosphamide and mesna 500 mg m-2 dose i.v. bolus 12 hr days 2–4
CYM 1+2
Cytarabine 100 mg m-2 day -. continuous infusion days 2–6
High-dose MTX 3 m-2 -. over 3 h day 1
Folinic acid rescue 15 mg m-2 i.v. from day 2
i.t. MTX + HC day 2
i.t. Cytarabine + HC day 7
COPADM 3 AS COPADM 1 (expect that
cyclophosphamide is given for 2 days only)
MTX – methotrexate; HC – hydrocortisone; I.T. – intrathecal; I.V. – intravenous
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Figure 1 Schema of the UKCCSG 9002 protocol
Intensified chemotherapy
± megatherapyet al, 1998), followed by high-dose chemo/radiotherapy and stem
cell rescue. Patients were formally assessed at the end of treatment
to confirm remission with 1–2 monthly review for the first year
after the end of treatment. The follow-up was by clinical examina-
tion and radiological imaging was only performed if there was
clinical concern.
All patients received appropriate supportive care immediately
after diagnosis. Antimicrobials, blood and platelet transfusions
and total parental nutrition (TPN) were used as indicated. During
induction therapy hyper-hydration was given using
dextrose–saline 3 l m–2 per day and allopurinol 10 mg kg–1 day–1.
Dialysis (peritoneal or haemodialysis) was performed according to
the clinical situation. No patient received prophylactic granulocyte
colony-stimulating factor (G-CSF).
Statistical methods
The main end point used to evaluate the protocol treatment was
event-free survival (EFS). This was defined as the length of time
from diagnosis to the earliest detection of relapse/progression or
death from any cause. Surviving relapse-free patients were
censored at the date of the last clinical follow-up and survival
curves were calculated by standard methods (Kaplan and Meier,
1958; Rothman, 1978). Univariate analysis was carried out using
the log-rank test (Peto et al, 1977) to evaluate the differences in
prognosis between patients in relation to the sub-stage – IIIA vs
IIIB vs IIIX; LDH level at diagnosis twice or more vs less than
twice the institutional upper limit normal (ULN) and the achieve-
ment of CR within less than 28 versus 28 days or more.
Multivariate analysis was carried out including all these factors
together to test for independent effects (SAS, 1991).
RESULTS
Six patients (5.4%) never achieved CR. All died 1–6 months from
diagnosis (median 3.6 months) except one who continued to have
residual lymphoma (biopsy proven) at the primary site. He went
into CR after high-dose chemotherapy/radiotherapy and autolo-
gous bone marrow rescue and is alive 2 years from diagnosis.
At the time of analysis, eight patients (7.1%) have relapsed after
achieving CR. Sites of relapse were combined primary site and
bone marrow (n = 2), bone marrow (n = 2), primary site (n = 3) and
one patient relapsed in the bone marrow, primary site and CNS.
Five of these eight patients died 6–14 months from diagnosis
(median 9.2 months) despite receiving subsequent more intensive
chemotherapy (n = 4) or high-dose chemo/radiotherapy with
autologous stem cell rescue (n = 1). Three are alive in CR after
receiving further intensive chemotherapy using the UKCCSG
9003 protocol or CHOP, followed by autologous stem rescue
(n = 2) or matched unrelated bone marrow (n = 1), 2–6 years from
diagnosis (median 3.6 years).
Toxicity
Three patients (2.7%) died of early toxicity. Causes of death were
disseminated aspergillosis at 35 days (n = 1), sepsis with post-
mortem evidence of anthracycline-induced cardiomyopathy at 30
days (n = 1) and peritonitis with renal cortical necrosis and
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Figure 2 Event free survival of all patients.congestive cardiac failure 52 days from diagnosis (n = 1). There
was one late death in a patient who developed chronic myeloid
leukaemia 21 months from diagnosis. He was treated with three
intensive blocks of AML-type chemotherapy with good initial
response, but no further treatment was given because of severe
cardiac toxicity. He subsequently progressed to develop an acute
myeloblastic crisis and died 15 months later. Acute mucosal and
myelotoxicity was significant, but managable as previously
reported (Patte et al, 1991).
Survival
With a median follow-up of 48 months (range 12–92), the overall
survival and EFS are 87% (95% confidence interval (CI)
79.2–92.1%) and 83.7% (95% CI 76.3–89.2%) respectively
(Figure 2). Results of univariate and multivariate analyses of EFS
are shown in Table 2.
LDH levels at diagnosis were available in 79 patients with a
range of 154–7575 iu l–1 (median 1118). The median time to
achieve CR was 70 days (range 7–181). The overall survival and
EFS are high and differences in EFS according to the three sub-
stages identified, LDH level or the time to achieve CR are small at
4 years from diagnosis (Figures 3, 4 and 5). The multivariate
analysis does not appear to change the conclusions from the
univariate analysis.
DISCUSSION
The consistent improvement in the prognosis of children with B-
NHL has been mainly due to the use of higher dose systemic
chemotherapy, frequent i.t. therapy and the reduction in early toxic
death by avoiding unnecessary surgery coupled with aggressive
treatment of biochemical and infectious complications soon after
diagnosis or during induction (Lynch et al, 1977; Hann et al, 1990;
Patte et al, 1991; Cairo et al, 1996; Miron et al, 1997). In the last
decade the emphasis has been on trying to find prognostic factors
that help to stratify patients and to deliver treatment according to
risk group. The SFOP classification subdivided patients with stage
Table 2 Results of univariate and multivariate analyses of EFS
Log rank P-value Relative risk P-value multivariate
Univariate multivariate
LDH (³vs<2 ULN) 0.75 0.85 0.76
CR 0.47 1.33 0.71
(>28 days vs <28 days)
Substage (IIIA vs IIIB) 0.82 0.56 0.64 (0.38)
(IIIX vs IIIB) 0.71 (0.67)
ULN – upper limit of normal
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Figure 3 Event free survival in relation to the substage
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III disease into two main groups, namely IIIA and IIIB, according
to the extent of primary disease (Philip et al, 1987). The German
BFM group used a similar approach by dividing patients with
stage III B-NHL into two risk groups based on LDH levels less
than or more than 500 u l–1 (Reiter et al, 1995). Children with LDH
less than 500 (R2 Regimen) and those with LDH more than 500 u
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P= 0.75, log-rank test
LDH < 2 × U.L.N (n= 44) LDH = > 2 × U.L.N (n= 35)
Figure 4 Event free survival in relation to serum LDH level at diagnosis
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Figure 5 Event free survival in relation to time to achieve CRl-1 (R3 Regimen) had EFS at 5 years of 95% and 68% respectively
(Reiter et al, 1997). The EFS for all stage III patients improved
from 73% in the BFM 86 study to 90% in the BFM 90 study where
the treatment was intensified.
A randomized prospective study by the CCG (CCG-503)
compared two chemotherapy regimens (COMP vs D-COMP) in
children with disseminated non-lymphoblastic NHL and no bone
marrow or CNS disease. This showed a 2-year EFS of 63%. Those
with bone marrow or CNS involvement were electively treated
with the D-COMP regimen and had a 2-year EFS of 48%
(Chilcote et al, 1991). Children with LDH of 500 or more, bone
marrow or CNS involvement and the presence of thoracic lymph
node enlargement had a poorer outcome.
The CCG also compared the results of treatment of children
with B-NHL and bone marrow or CNS involvement in a random-
ized study using the LMB-89 and CCG hybrid designated the
‘Orange’ protocol. There was no significant difference in EFS
between the two groups, but longer duration of hospitalization and
more toxicity was recorded with the former (Cairo et al, 1996).
Poorer outcome was associated with serum LDH greater than
twice institutional norms and CNS involvement.
The POG-86 Study involved 133 children with B-ALL (n = 74)
and stage IV B-NHL (n= 59) treated with intensified systemic and i.t.
chemotherapy including low-dose continuous infusion cytarabine.
Sixty-three patients had abdominal disease and 36 had CNS involve-
ment at diagnosis. The EFS for children with B-ALL and stage IV B-
NHL was 65% and 79% respectively (Bowman et al, 1996).
In the UKCCSG NHL-86 study, children with Murphy stage III
B-NHL were treated with standard dose chemotherapy (n = 28)
including 15 with extensive multiorgan disease or a more intensive
regimen (MACHO) (n = 16), 14 with multiorgan involvement.
The EFS was 76% with a lower relapse rate in the latter group (6%
vs 21%) (Hann et al, 1990; Pinkerton et al, 1991).
In the early 1990s, the UKCCSG adopted the French LMB 84
protocol for the treatment of children with advanced stage B-NHL
with the aim of both reproducing the excellent SFOP results and to
study the prognostic significance of LDH level at diagnosis,
substage and the time to achieve CR. In addition to the previous
sub-stages IIIA and IIIB, patients with extra abdominal disease
were classified as IIIX. Univariate and multivariate analyses
showed no evidence of prognostic value for substage, time to
achieve CR or LDH. The limited number of patients with known
LDH might have contributed to the lack of prognostic significance
of LDH level. Another aim of the study was to attempt to reduce
early toxic death rate by preventing tumour lysis syndrome during
early induction and aggressive treatment of infectious and renal
complications, which had appeared to be higher in the previous
UKCCSG experience (Hann et al, 1990; Pinkerton et al, 1991),
than with the LMB studies (Philip et al, 1987). Three patients
(2.7%) died due to treatment-related toxicity, compared with
reported rates of 6–8% in previous UKCCSG studies. This reduc-
tion is encouraging but efforts need to be made to reduce it even
further, e.g. the use of urate oxidase (uricozyme). The relapse rate
of 7.1% in our study is comparable to that in SFOP studies, and
CNS relapse of less than 1% remains low despite the absence of
cranial radiotherapy. Three of the relapsed patients in this study
were salvaged with more intensive chemotherapy, followed by
high-dose chemo/radiotherapy and a stem cell rescue confirming
previous reports that relapsed patients after less intensive first-line
therapy may be cured with more intensive chemotherapy (Philip
et al, 1993; Sweetenham et al, 1994).
We conclude that with a short LMB type regimen of moderately
intensive multi-agent chemotherapy, patients with a stage III and
IV (blasts less than 70%) B-NHL have an excellent prognosis and
as therapy has become more intensive and effective, the signifi-
cance of various prognostic factors disappear. The priority in this
group is to try and reduce both early and late morbidity. This is the
aim of the current UK, French and US collaboration (FAB LMB
96) where reduction in both dose intensity and duration are evalu-
ated in a randomized study. It is apparent that, with such effective
chemotherapy, no clear prognostic subgroups can be identified at
presentation. Something could emerge in the eventual analysis of
FAB LMB 96 where treatment has been reduced for some patients.
It is important that new approaches are found for relapsed patients,
although few in number, the salvage rate for these patients remains
relatively poor.
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